Loading...
Soleno Therapeutics, Inc.
SLNO•NASDAQ
Healthcare
Biotechnology
$86.47
$-1.56(-1.77%)
Soleno Therapeutics, Inc. (SLNO) Financial Performance & Income Statement Overview
Review Soleno Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-345.65%
↓ 345.65%
Net Income Growth
-351.04%
↓ 351.04%
Operating Cash Flow Growth
-177.05%
↓ 177.05%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-77.52%
↓ 77.52%
ROIC
-53.76%
↓ 53.76%
Soleno Therapeutics, Inc. (SLNO) Income Statement & Financial Overview
Review Soleno Therapeutics, Inc.'s (SLNO) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $494000.00 | $490000.00 |
| Gross Profit | $0.00 | $0.00 | -$494000.00 | -$490000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $21.49M | $30.14M | $12.34M | $14.60M |
| SG&A Expenses | $37.30M | $49.20M | $10.39M | $8.47M |
| Operating Expenses | $59.12M | $80.21M | $22.74M | $23.48M |
| Total Costs & Expenses | $59.12M | $80.21M | $23.23M | $23.48M |
| Interest Income | $3.37M | $3.60M | $3.01M | $2.08M |
| Interest Expense | $231000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $503000.00 | $500000.00 | $494000.00 | $490000.00 |
| EBITDA | -$55.25M | -$78.83M | -$22.74M | -$22.58M |
| EBITDA Ratio | ||||
| Operating Income | -$59.12M | -$80.21M | -$23.23M | -$21.40M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $3.13M | $3.60M | $1.38M | $2.08M |
| Income Before Tax | -$55.98M | -$76.62M | -$21.85M | -$21.40M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.19M |
| Net Income | -$55.98M | -$76.62M | -$21.85M | -$21.40M |
| Net Income Ratio | ||||
| EPS | -$1.27 | -$1.83 | -$0.57 | -$0.59 |
| Diluted EPS | -$1.27 | -$1.83 | -$0.57 | -$0.59 |
| Weighted Avg Shares Outstanding | $43.92M | $41.88M | $38.63M | $36.21M |
| Weighted Avg Shares Outstanding (Diluted) | $43.92M | $41.88M | $38.63M | $36.21M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan